CTLA-4 Binding Antibodies Optimizing Affinity and Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CTLA-4 antagonists have limitations in terms of affinity, specificity, and developability, and there is a need for more effective therapeutics that inhibit CTLA-4 signaling activity with minimal adverse side effects.
Innovation Solution
Development of isolated monoclonal antibodies with a CD152-binding domain, specifically designed to bind to human CD152 with high affinity, potentially outperforming existing antibodies like ipilimumab in terms of binding strength and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current CTLA-4 antagonists are used, then T cell suppression can be blocked, but affinity and specificity are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody structure to achieve higher binding affinity (lower Kd values) and improved specificity for CTLA-4. The engineered antibodies demonstrate enhanced binding parameters compared to existing antagonists, resolving the contradiction between reliability and harmful effects through precise molecular parameter optimization.
2Productivity
If CTLA-4 signaling is inhibited, then antitumor immune response is enhanced, but adverse side effects increase
Solution Approach 1:
The patent applies local quality by designing antibodies with optimized binding characteristics that target CTLA-4 specifically with high precision. The enhanced specificity ensures that the antitumor efficacy is achieved through localized and precise immune modulation, reducing off-target effects and adverse side effects while maintaining high productivity in tumor cell elimination.
3Reliability
If existing anti-CTLA-4 antibodies are used, then treatment can proceed, but affinity and developability are limited
Solution Approach 1:
The patent applies parameter changes by systematically optimizing multiple antibody parameters simultaneously, including binding affinity, stability, and developability characteristics. The engineered antibodies achieve superior binding affinity while maintaining improved developability properties, resolving the contradiction between reliability and ease of manufacture through comprehensive parameter optimization.
Data Source
AI summary
Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.